Objective To analyze the expression and clinical significance of serum exosomal circular RNA hsa_circ_0018430 in lung squamous cell carcinoma(LSCC).Methods From March 2020 to October 2022,tumor tissues and serum samples were collected from patients with LSCC.Serum exosomes were extracted,and the morphology and particle size distribution of serum exosomes were characterized by transmission electron microscopy,NTA,and western blot.Quantitative real-time PCR(qPCR)was used to detect the relative expression of hsa_circ_0018430.The receiver operating characteristic(ROC)curve and clinical significance of hsa_circ_0018430 in serum exosomes were used to analyze the efficacy of hsa_circ_0018430 in diagnosing LSCC.ELISA assays were used to detect the expression of BICC1 in LSCC.Results The relative expression level of serum exosomal hsa_circ_0018430 in LSCC patients was significantly higher than that in healthy controls[3.928(2.553～5.303)vs.1.823(0.798～2.848),P＜0.001],sensitivity 86.51％,specificity 91.37％.According to the ROC analysis,the AUC of hsa_circ_0018430 expression for distinguishing LSCC from healthy controls was 0.881(95％CI:0.809～0.952,P＜0.001).The level of serum exosomal hsa_circ_0018430 was correlated with TNM stage,lymphatic metastasis and serum CEA level(P＜0.05),but not with age,sex,tumor size,and smoking history(P＞0.05).The TCGA database analysis showed the significant impaired BICC1 expression in LSCC patients(P＜0.05),and there was no significant association between the expression level of BICC1 and TNM stage and overall survival(P＞0.05).The expression level of BICC1 in cancer tissues of 46 LSCC patients was significantly down-regulated compared with that in adjacent tissues by ELISA assays(P＜0.05).Conclusion The serum exosomal hsa_circ_0018430 expression level in LSCC patients is increased,which is expected to be the valuable new biomarkers for the diagnosis and treatment of LSCC.
维普
万方数据
